NCT01336959 - Safety & Efficacy of BCT197 in Patients Undergoing Cardiac Surgery | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

November 30, 2013

Study Completion Date

November 30, 2013

Conditions

Acute Kidney Injury

Interventions

DRUG

BCT197 Part A

open label single dose administration of 10mg BCT197, 2 hours prior to surgery

DRUG

Placebo

Single dose matching placebo administered 2 prior to surgery

DRUG

BCT197 Part B

BCT197 50mg single dose administered 2 hours prior to surgery

Trial Locations (13)

Novartis Investigative Site, Taipei

Novartis Investigative Site, Wynnewood

Novartis Investigative Site, Falls Church

Novartis Investigative Site, Cleveland

Novartis Investigative Site, Saginaw

Novartis Investigative Site, Petah Tikva

Novartis Investigative Site, Lincoln

Novartis Investigative Site, Tel Aviv

Novartis Investigative Site, Rehovot

Novartis Investigative Site, Beersheba

Novartis Investigative Site, Jerusalem

Novartis Investigative Site, Orange

Novartis Investigative Site, Herzliya